Black Rock Inc. Armata Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Armata Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 22,921 shares of ARMP stock, worth $47,675. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,921

Previous 23,868 3.97%

Holding current value

$47,675

Previous $99,000 36.36%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$2.4 - $3.9 $2,272 - $3,693	-947 Reduced 3.97%	22,921 $63,000
Q1 2024 May 10, 2024	BUY	$2.81 - $4.18 $3,113 - $4,631	1,108 Added 4.87%	23,868 $99,000
Q4 2023 Feb 13, 2024	SELL	$1.95 - $3.24 $518 - $861	-266 Reduced 1.16%	22,760 $73,000
Q3 2023 Nov 13, 2023	SELL	$1.1 - $4.35 $1,529 - $6,046	-1,390 Reduced 5.69%	23,026 $69,000
Q2 2023 Aug 11, 2023	SELL	$1.14 - $1.7 $1,085 - $1,618	-952 Reduced 3.75%	24,416 $27,000
Q1 2023 May 12, 2023	BUY	$1.1 - $3.58 $897 - $2,921	816 Added 3.32%	25,368 $42,000
Q4 2022 Feb 13, 2023	BUY	$0.94 - $4.16 $511 - $2,263	544 Added 2.27%	24,552 $30,000
Q3 2022 Nov 14, 2022	BUY	$3.12 - $4.92 $7,394 - $11,660	2,370 Added 10.95%	24,008 $101,000
Q2 2022 Aug 12, 2022	SELL	$2.97 - $5.4 $8,984 - $16,335	-3,025 Reduced 12.27%	21,638 $84,000
Q1 2022 May 12, 2022	SELL	$3.9 - $6.32 $4,668 - $7,565	-1,197 Reduced 4.63%	24,663 $121,000
Q4 2021 Feb 10, 2022	BUY	$2.96 - $5.86 $15,655 - $30,993	5,289 Added 25.71%	25,860 $142,000
Q3 2021 Nov 09, 2021	BUY	$3.55 - $4.14 $65,923 - $76,879	18,570 Added 928.04%	20,571 $74,000
Q2 2021 Aug 11, 2021	BUY	$3.89 - $4.87 $7,783 - $9,744	2,001 New	2,001 $8,000

Others Institutions Holding ARMP

# of Institutions

Shares Held

740K

Call Options Held

300

Put Options Held

View Full List

About Armata Pharmaceuticals, Inc.

Ticker ARMP
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,144,700
Market Cap $75.2M
Description
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus ...

More about ARMP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account